Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_assertion description "[Taken together, these results suggest that targeted delivery of 4-1BBL to the tumor site, when combined with anti-CD3/anti-CD20 diabody, could strongly potentiate the antitumor activity of the diabody, thus may have significant clinical application in the treatment of human CD20-positive B-cell malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_assertion evidence source_evidence_literature NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_assertion SIO_000772 20463597 NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_assertion wasDerivedFrom befree-20140225 NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_assertion wasGeneratedBy ECO_0000203 NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.
- befree-20140225 importedOn "2014-02-25" NP666354.RAlbJSZIwIKPKZRJ8nX93waGy9Gg8Vv56uK-CEaFStPbM130_provenance.